| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Cirsimarin targets multiple pathways involved in lipid metabolism and inflammation. It acts as an antagonist of the adenosine A1 receptor, which is involved in the regulation of lipolysis and脂肪 accumulation. It also inhibits phosphodiesterase, an enzyme that breaks down cyclic nucleotides, leading to increased cAMP levels. These actions contribute to its antilipogenic effects and reduction of adipose tissue deposition.
|
|---|---|
| ln Vitro |
In vitro, cirsimarin has potent antilipogenic effects. It acts as an antagonist of the adenosine A1 receptor and inhibits phosphodiesterase. Its activity is typically evaluated using adipocyte differentiation assays, where lipid accumulation is measured by Oil Red O staining. Receptor binding assays are used to assess A1 receptor antagonism. Phosphodiesterase inhibition is measured using enzyme activity assays. However, specific IC50 values are not extensively reported.
|
| ln Vivo |
In vivo, cirsimarin decreases adipose tissue deposition in mice. It has potent antilipogenic effects. These properties make it a potential candidate for the treatment of obesity. However, specific in vivo efficacy data, including dosing regimens and animal models, are not extensively detailed in the available literature. Further studies are needed to fully characterize its in vivo pharmacological profile. The compound is a research tool for studying obesity and lipid metabolism.
|
| Enzyme Assay |
Cell-free assays for cirsimarin involve evaluating its adenosine A1 receptor antagonism and phosphodiesterase inhibition. Receptor binding assays are performed using membrane preparations expressing adenosine A1 receptors. Phosphodiesterase activity is measured using enzyme activity assays with cyclic nucleotide substrates. The compound's chemical purity and identity are confirmed by HPLC, NMR, and mass spectrometry. It is typically dissolved in DMSO for assay preparation.
|
| Cell Assay |
In vitro cellular assays for cirsimarin typically involve treating adipocytes or preadipocytes with various concentrations of the compound. Adipocyte differentiation is assessed by Oil Red O staining and measurement of adipogenic markers. Lipid accumulation is quantified. Receptor binding and phosphodiesterase inhibition are assessed in cell-based assays. The compound is typically dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for cirsimarin are conducted in mouse models of obesity. The compound is administered via various routes including oral gavage or intraperitoneal injection. Adipose tissue deposition is measured by weighing fat pads and histological analysis. Body weight and metabolic parameters are monitored. However, specific dosing regimens and experimental protocols are not extensively documented in the available literature. Standard protocols for evaluating anti-obesity agents would typically be employed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of cirsimarin include a molecular weight of 476.4 g/mol and molecular formula C23H24O11. As a flavonoid glycoside, it is expected to have moderate oral bioavailability. The compound is stable as a powder at -20°C for 3 years or at 4°C for 2 years; in solvent, it is stable at -80°C for 6 months or at -20°C for 1 month. Detailed ADME parameters are not extensively reported.
|
| Toxicity/Toxicokinetics |
The toxicity profile of cirsimarin has not been extensively characterized in published literature. As a natural flavonoid, it is generally considered to have a favorable safety profile at research doses. Standard preclinical safety studies would include acute and sub-chronic toxicity assessments in rodent models. The compound is intended for research use only and not for therapeutic applications in humans.
|
| References | |
| Additional Infomation |
Cirsimarin is a glycoside belonging to the flavonoid class of compounds. It has been reported to be found in Cirsium japonicum, Micrococcus pumila, and other organisms with relevant data.
Cirsimarin is a flavonoid glycoside with potent antilipogenic effects that decreases adipose tissue deposition in mice. It acts as an adenosine A1 receptor antagonist and inhibits phosphodiesterase. Its molecular formula is C23H24O11 with a molecular weight of 476.4 g/mol. Cirsimarin is a research tool for studying obesity and lipid metabolism. It is not for therapeutic use. |
| Molecular Formula |
C23H24O11
|
|---|---|
| Molecular Weight |
476.4301
|
| Exact Mass |
476.132
|
| CAS # |
13020-19-4
|
| PubChem CID |
159460
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.523g/cm3
|
| Boiling Point |
767.1ºC at 760 mmHg
|
| Flash Point |
265.8ºC
|
| Vapour Pressure |
9.47E-25mmHg at 25°C
|
| Index of Refraction |
1.657
|
| LogP |
0.361
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
34
|
| Complexity |
736
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)OC
|
| InChi Key |
RETJLKUBHXTIGH-FZFRBNDOSA-N
|
| InChi Code |
InChI=1S/C23H24O11/c1-30-15-8-14-17(19(27)22(15)31-2)12(25)7-13(33-14)10-3-5-11(6-4-10)32-23-21(29)20(28)18(26)16(9-24)34-23/h3-8,16,18,20-21,23-24,26-29H,9H2,1-2H3/t16-,18-,20+,21-,23-/m1/s1
|
| Chemical Name |
5-hydroxy-6,7-dimethoxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0989 mL | 10.4947 mL | 20.9894 mL | |
| 5 mM | 0.4198 mL | 2.0989 mL | 4.1979 mL | |
| 10 mM | 0.2099 mL | 1.0495 mL | 2.0989 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
